Table 5.
Summary of parameter distributions for costs (in 2010 euros) used in the PSA
|
Costs of resources |
Parameter |
Expected costs (€) (standard error) |
|||
|---|---|---|---|---|---|
| |
|
After THR |
After TKR |
||
| Hospital perspective | SHI perspective | Hospital perspective | SHI perspective | ||
| Prophylaxis costs with enoxaparin in the case of | |||||
| Post-discharge VTE or no VTE and no MB |
par_14 |
0 |
106.42 (10.64) |
0 |
1.63 (0.16) |
| Prophylaxis costs with rivaroxaban in the case of | |||||
| MB with or without VTE |
par_15 |
13.00 (1.30) |
0 |
13.00 (1.30) |
0 |
| Pre-discharge VTE without MB |
par_16 |
18.20 (1.82) |
0 |
18.20 (1.82) |
0 |
| Post-discharge VTE or no VTE and no MB |
par_17 |
32.24 (3.22) |
134.85 (13.49) |
33.02 (3.30) |
2.06 (0.21) |
| Total costs of pre-discharge VTE | |||||
| DVT |
par_18 |
1,282.27 (128.33) |
157.35 (17.74) |
1,115.14 (111.51) |
157.40 (15.74) |
| Non-fatal PE |
par_19 |
2,105.22 (210.52) |
157.23 (15.73) |
2,362.79 (236.28) |
348.40 (34.84) |
| Total costs of post-discharge VTE |
|
|
|
|
|
| DVT |
par_20 |
0 |
1,995.89 (199.59) |
0 |
1,995.89 (199.59) |
| Non-fatal PE |
par_21 |
0 |
3,700.43 (370.04) |
0 |
3,700.43 (370.04) |
| Fatal PE | par_22 | 0 | 1,256.43 (125.64) | 0 | 1,256.43 (125.64) |
PSA = probabilistic sensitivity analysis, THR = total hip replacement, TKR = total knee replacement, SHI = social health insurance, VTE = venous thromboembolism, MB = major bleeding, DVT = deep vein thrombosis, PE = pulmonary embolism.